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ABSTRACT
Fast and accurate diagnostic systems are needed for further implementation 
of precision therapy of BRAF-mutant and other cancers. The novel IdyllaTM BRAF 
Mutation Test has high sensitivity and shorter turnaround times compared to other 
methods. We used Idylla to detect BRAF V600 mutations in archived formalin-fixed 
paraffin-embedded (FFPE) tumor samples and compared these results with those 
obtained using the cobas 4800 BRAF V600 Mutation Test or MiSeq deep sequencing 
system and with those obtained by a Clinical Laboratory Improvement Amendments 
(CLIA)-certified laboratory employing polymerase chain reaction–based sequencing, 
mass spectrometric detection, or next-generation sequencing. In one set of 60 FFPE 
tumor samples (15 with BRAF mutations per Idylla), the Idylla and cobas results 
had an agreement of 97%. Idylla detected BRAF V600 mutations in two additional 
samples. The Idylla and MiSeq results had 100% concordance. In a separate set of 
100 FFPE tumor samples (64 with BRAF mutation per Idylla), the Idylla and CLIA-
certified laboratory results demonstrated an agreement of 96% even though the 
tests were not performed simultaneously and different FFPE blocks had to be used for 
9 cases. The IdyllaTM BRAF Mutation Test produced results quickly (sample to results 
time was about 90 minutes with about 2 minutes of hands on time) and the closed 
nature of the cartridge eliminates the risk of PCR contamination. In conclusion, our 
observations demonstrate that the Idylla test is rapid and has high concordance with 
other routinely used but more complex BRAF mutation–detecting tests.
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INTRODUCTION
With the identification of druggable molecular 
aberrations in cancer, we have increased our understanding 
of cancer biology and identified novel molecular targets 
for cancer therapy. [1–6] In particular, the identification 
of the BRAF V600 mutation hotspot in melanoma and 
other malignancies has led to the development of small-
molecule kinase inhibitors targeting the BRAF oncogene. 
These BRAF inhibitors have revolutionized therapy for 
patients with BRAF V600–mutant advanced melanoma 
and demonstrated promising results in patients with 
other BRAF mutation–harboring diseases, including 
histiocytosis, hairy cell leukemia, non–small cell lung 
cancer, and biliary cancer. [4, 7–10]
BRAF inhibitors are contraindicated in the absence 
of a BRAF mutation. To determine whether a disease 
harbors a BRAF mutation, and thus whether treatment 
with BRAF inhibitors is appropriate, various methods 
to detect BRAF mutations in archived formalin-fixed, 
paraffin-embedded (FFPE) tissue samples are used. 
However, the methods that are currently routinely used 
for this purpose often require several hours to perform 
owing to time-consuming steps that include incubation, 
pipetting, and other processes. [11] In addition, for these 
molecular testing methods to be cost-effective, they are 
often performed on batches of samples, rather than single 
samples, thereby further increasing the turnaround time 
from sample to result. Consequently, results from these 
tests may not be available for at least several days or 
even weeks. [12] Such delays can hinder the delivery of 
effective treatment and thus have negative implications 
for care, especially in patients with a rapidly progressing 
disease such as advanced melanoma. [13]
A faster and simplified method for detecting BRAF 
mutations in FFPE tumor samples is the novel, fully 
integrated, real-time polymerase chain reaction (PCR)-
based IdyllaTM system. Unlike current routinely used 
technologies for BRAF mutation detection, the IdyllaTM 
BRAF Mutation Test does not require manual sample 
preprocessing steps such as deparaffinization, FFPE tissue 
digestion, or DNA extraction because all these steps are 
integrated within a single-use cartridge. A complete FFPE 
tissue section or macrodissected FFPE material is placed 
directly into the cartridge and is subsequently processed 
by the IdyllaTM system, which provides automated sample 
processing, real-time PCR–based mutation detection, and 
result reporting. In the present study, we compared the 
performance of the IdyllaTM BRAF Mutation Test with that 
of other routinely used diagnostic methods for detecting 
BRAF V600 mutations.
RESULTS
Analytical sensitivity and specificity
To determine the sensitivity of the IdyllaTM BRAF 
Mutation Test (hereafter referred to as Idylla) in detecting 
BRAF V600 mutations in FFPE material, we used the 
test to analyze eight different sections of commercially 
available FFPE cell-line blends containing wild-type 
BRAF only, 1% BRAF V600E or 1% BRAF V600K in 
a wild-type BRAF background and demonstrated 100% 
agreement among eight independent experiments for each 
respective mutation (Table 1, Figure 1A–C).
To assess the reproducibility of the Idylla TMBRAF 
V600 Mutation Test across different IdyllaTM instruments 
and among different operators, three operators used the 
test to repeatedly analyze consecutive sections from the 
same control 1% BRAF V600K FFPE sample 139 times 
on 7 different instruments using cartridges from two 
different production batches. BRAF V600K mutations 
were identified in 100% of the sections, indicating the high 
reproducibility of the test’s results, even in cases with low 
abundant mutations, regardless of instrument and operator 
variation (Supplementary Figure S1).
To determine the specificity of the IdyllaTM BRAF 
Mutation Test in detecting BRAF V600 mutations, we 
used the test to analyze a high number of wild-type BRAF 
genomic DNA copies (8 × 104 per PCR reaction) from 
the BRAF wild-type CHL-1 cell line to identify the extent 
of cross-reactivity between the BRAF wild-type allele and 
the BRAF V600E and V600K reactions. Unlike the DNA 
recovered from FFPE samples, which is degraded by the 
formalin fixation and only partially amplifiable by PCR, 
the unfixed, high-quality genomic DNA recovered from 
the CHL-1 cell line enabled us to maximally challenge 
the specificity of the assay. In this experiment, the delta 
Ct between the specific signal of the BRAF V600 wild-
type reaction and the cross-reactivity signal in the BRAF 
V600E and BRAF V600K reactions was greater than 20, 
demonstrating that the mutation detection reactions are 
highly specific even in the presence of a high number of 
wild-type alleles (Supplementary Figure S2).
Table 1: Performance of the IdyllaTM BRAF Mutation Test on control formalin-fixed, paraffin-
embedded samples containing 1% or no BRAF V600 mutation
Control sample V600E mutation detected V600K mutation detected No mutation detected
1% BRAF V600E 8/8 0/8 0/8
1% BRAF V600K 0/8 8/8 0/8
BRAF V600 wild-type 0/8 0/8 8/8
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Performance of Idylla versus cobas and MiSeq
We initially tested the IdyllaTM BRAF Mutation 
Test (hereafter referred to as Idylla) capacity to detect 
BRAF V600 mutations using 73 unprocessed (i.e., without 
macro- or micro dissection) FFPE tumor samples from 
patients with diverse cancers (melanoma, n = 30; colorectal 
cancer, n = 23; non-small cell lung cancer [NSCLC], 
n = 12; papillary thyroid cancer, n = 5; breast cancer, 
n = 3) obtained from commercial suppliers as outlined in 
Methods section (Table 2). No samples produced an invalid 
result. Idylla detected BRAF V600 mutations in 12 of 30 
melanomas (40%), 1 of 23 colorectal cancers (4%), and 2 of 
5 papillary thyroid cancers (40%) but did not detect BRAF 
V600 mutations in breast cancers or NSCLC.
From the 73 FFPE tumor samples, we randomly 
selected 45 samples with wild-type BRAF and all 15 
samples with BRAF V600 mutations as per Idylla and 
Figure 1: Representative examples of polymerase chain reaction curves for formalin-fixed paraffin-embedded cell line 
mixtures containing A. wild-type BRAF, B. 1% BRAF V600E, or C. 1% BRAF V600K. WT, wild type.
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subjected these 60 samples to the cobas BRAF V600 
Mutation Test, a U.S. Food and Drug Administration–
approved companion diagnostic, according to manu-
facturer’s instructions. The sample size of 60 samples 
was expected to be adequate to demonstrate concordance 
of 95%–100% (kappa 0.9, 95% confidence interval [CI] 
+/– 0.15). To help maximize the sensitivity of the cobas 
test, we used macrodissection to enrich the tumor area 
of 42 of the 60 tumor samples (70%). Of these 60 FFPE 
tumor samples, 2 (1 melanoma and 1 breast cancer) could 
not be analyzed with cobas owing to insufficient DNA 
concentrations. For 56 of the remaining 58 samples (97%), 
the Idylla and cobas results were in overall agreement 
(kappa 0.91, standard error [SE], 0.07, 95% CI, 0.78–
1.00). Compared with Idylla, cobas had a sensitivity of 
87% (95% CI, 0.60–0.98), specificity of 100% (95% 
CI, 0.92–1.00), positive predictive value of 100% (95% 
CI, 0.75–1.00), and negative predictive value of 96% 
(95% CI, 0.85–0.99; Table 3). Of interest, the 2 samples 
in which Idylla but not cobas detected BRAF mutations 
(1 BRAF V600E mutation and 1 BRAF V600R mutation) 
contained less than 25% tumor cells. As described below, 
the Idylla results for both these samples were confirmed 
using an independent method.
To validate the results obtained with Idylla and 
cobas, we subjected the 60 FFPE tumor samples (45 with 
wild-type BRAF and 15 with BRAF V600 mutations as 
per Idylla) to mutation analysis using the MiSeq deep 
sequencing system, in which the BRAF V600–surrounding 
region was amplified by PCR and sequenced at high 
depth (coverage >5000x) to facilitate the identification of 
mutations present in at least 1% of the DNA. Of these 60 
samples, 2 had insufficient coverage and were excluded 
from further analysis. For the remaining 58 samples, 
the Idylla and MiSeq results demonstrated an overall 
agreement of 100% (kappa 1.00, SE 0.00; 95% CI, 1.00–
1.00). Compared with MiSeq, Idylla had a sensitivity of 
100% (95% CI, 0.78–1.00), specificity of 100% (95% CI, 
0.92–1.00), positive predictive value of 100% (95% CI, 
0.78–1.00), and negative predictive value of 100% (95% 
CI, 0.92–1.00; Table 3). The MiSeq analysis also revealed 
that the two low-tumor-cellularity samples in which Idylla 
but not cobas had identified a BRAF mutation contained 
4.6% V600E and 5.7% V600R, respectively, which is in 
line with the overall specifications of the cobas test.
Independent clinical validation of the IdyllaTM 
BRAF mutation test
We then used Idylla in a retrospective study 
to test FFPE tumor samples from 100 patients with 
advanced cancers (melanoma, n = 38; colorectal 
cancer, n = 25; papillary thyroid carcinoma, n = 12; 
ovarian cancer, n = 5; cholangiocarcinoma, n = 3; head 
and neck cancer, n = 3; gastrointestinal stromal tumor, 
n = 2; NSCLC, n = 2; other, n = 10, Table 4) whose 
BRAF V600 mutation status had been previously 
determined in MD Anderson’s Clinical Laboratory 
Improvement Amendments (CLIA)-certified Molecular 
Diagnostics Laboratory from routine clinical biopsies 
and resections. The CLIA laboratory detected BRAF 
V600 mutations in 66 of the 100 specimens (66%), 
and Idylla detected BRAF V600 mutations in 63 of the 
specimens (63%). The results of Idylla and the CLIA 
laboratory had overall agreement in 96 cases (96%; 
kappa, 0.91, SE, 0.04; 95% CI, 0.83–1.00). Compared 
with the CLIA laboratory, Idylla had a sensitivity of 
95% (95% CI, 0.87–0.99), specificity of 97% (95% CI, 
0.85–1.00), positive predictive value of 98% (95% CI, 
0.91–1.00), and negative predictive value of 92% (95% 
CI, 0.79–0.98; Table 3). We always attempted to obtain 
the identical tissue blocks that were used by the CLIA 
laboratory for testing with Idylla; however, this was 
not possible in 9 cases. Of interest, of the 9 samples 
for which a different block was analyzed by the Idylla 
test, only 1 had discrepant results with the CLIA 
laboratory (BRAF V600K by CLIA, but wild-type by 
Idylla) resulting in an overall agreement of 89% for 
this subset (Supplementary Table S1). One (colorectal 
cancer with BRAF V600K mutation by the CLIA, 
but not Idylla) of four patients with discrepant BRAF 
V600 mutation status between the CLIA laboratory 
and Idylla received a MEK inhibitor with disease 
progression and one patient (melanoma with BRAF 
V600E mutation by the CLIA, but not Idylla) received 
a combination of BRAF inhibitor with chemotherapy 
and responded for 3 months. In addition, a patient 
with prostate carcinoma (BRAF V600E mutation by 
the CLIA, but not Idylla) and colorectal cancer (BRAF 
V600E mutation by the Idylla, but not CLIA) never 
received BRAF or MEK inhibitors.
Table 2: BRAF V600 mutations in different tumor types detected by Idylla
Tumor type (n) BRAF V600E BRAF V600K/R BRAF V600 wild-type
Melanoma (30) 9 3 18
Colorectal cancer (23) 1 0 22
Lung cancer (12) 0 0 12
Thyroid cancer (5) 2 0 3
Breast cancer (3) 0 0 3
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DISCUSSION
The present study’s findings demonstrate that the 
IdyllaTM BRAF Mutation Test can reproducibly detect 
BRAF V600 mutations in FFPE samples with as little as 
1% mutant DNA in a wild-type background and that the 
test’s performance is on par with that of other routinely 
used but more complex methods of BRAF mutation 
detection.
First, we found an overall agreement of 97% 
between Idylla and cobas on 60 FFPE tumor samples. 
Idylla detected BRAF V600 mutations (4.6% V600E and 
5.7% V600R according to MiSeq) in two samples that had 
relatively low tumor cellularity and that cobas identified as 
having wild-type BRAF, plausibly due to the test’s higher 
detection limit (at least 5% of V600E mutant DNA) and 
because cobas is not validated for the detection of V600R. 
Furthermore, the Idylla results were confirmed using the 
MiSeq next-generation sequencing platform with 100% 
concordance. In an independent study, we found an overall 
agreement of 96% between Idylla and a CLIA-certified 
laboratory on 100 FFPE samples despite the fact that 
the testing was not performed simultaneously and that a 
different block had to be used for Idylla testing in 9% of 
cases. Although intratumoral heterogeneity for the BRAF 
V600 mutation might confound the concordance analysis, 
this effect appears to have a limited impact in our study, 
since the overall agreement level between both tests 
reached 96%. [14]
The workflow complexities and turnaround times 
of the different BRAF mutation–detecting methods used 
in the present study differ considerably. Unlike the FFPE 
sample processing steps in methods such as cobas, the 
FFPE sample processing steps in Idylla are completely 
integrated within one cartridge, which eliminates 
the need for manually performing time-consuming 
procedures such as deparaffinization, tissue digestion, 
and DNA extraction. Both the cobas test and MiSeq 
platform require a separate upfront DNA extraction 
step, which can take up to 3 hours, including about 
1 hour for manual pipetting and incubation; subsequent 
PCR testing requires an additional 2 hours, including 
30 minutes for manual procedures, when cobas is 
used. While these procedures are mostly performed in 
a sample batching mode, Idylla allows random access 
analysis of individual samples, leading to a turnaround 
time of hours instead of up to several weeks. The MiSeq 
workflow is even more complex and time-consuming 
Table 3: Concordance between Idylla and other methods in detecting BRAF V600 mutations in 
formalin-fixed paraffin-embedded (FFPE) tumor tissue samples
Concordance between cobas and Idylla testing of FFPE tumor tissue samples (N = 58)
BRAF mutation (cobas) BRAF wild-type (cobas)
BRAF mutation (Idylla) 13 2
BRAF wild-type (Idylla) 0 43
Observed agreements 56 (97%); kappa, 0.91, SE, 0.07; 95% CI, 0.78–1.00
Concordance between MiSeq and Idylla testing of FFPE tumor tissue samples (N = 58)
BRAF mutation (MiSeq) BRAF wild-type (MiSeq)
BRAF mutation (Idylla) 15 0
BRAF wild-type (Idylla) 0 43
Observed agreements 58 (100%); kappa, 1.00, SE, 0.00; 95% CI, 1.00–1.00
Concordance between laboratory and Idylla testing of FFPE tumor tissue samples (N = 100)
BRAF mutation (CLIA) BRAF wild-type (CLIA)
BRAF mutation (Idylla) 61 1
BRAF wild-type (Idylla) 3 35
Observed agreements 96 (96%); kappa, 0.91, SE, 0.04; 95% CI, 0.83–1.00
Sensitivity 95% (95% CI, 0.87–0.99)
Specificity 97% (95% CI, 0.85–1.00)
Positive predictive value 98% (95% CI, 0.91–1.00)
Negative predictive value 92% (95% CI, 0.79–0.98)
Abbreviations: SE, standard error; CI, confidence interval.
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than that of cobas owing to the different steps needed 
for preparing the sequencing library and performing the 
sequencing itself. In addition, for both cobas and MiSeq, 
the use of separate pre-PCR and post-PCR rooms to 
prevent sample contamination is strongly recommended. 
In contrast, the IdyllaTM BRAF Mutation Test produces 
results in about 90 minutes with about 2 minutes of 
hands on time and the closed nature of the cartridge 
eliminates the risk of PCR contamination. Furthermore, 
given its simple workflow and quick turnaround time, 
the IdyllaTM system can be used at nearly any facility, 
including those that would not be able to implement 
technologies with more complex workflows such as 
cobas or MiSeq.
Although Idylla detects BRAF V600E, V600K, 
V600R, V600M, and V600D mutations, it does not 
distinguish between BRAF mutations occurring on the 
same nucleotide, i.e., the V600E/D or V600K/R/M 
mutations. However, this is clinically acceptable, because 
patients carrying either one of these mutations have been 
reported to benefit from treatment with a BRAF inhibitor.
[15] Whereas the MiSeq platform can detect all of these 
mutations, the cobas test only detects BRAF V600E down 
to at least 5% of mutant allele and BRAF V600K down 
to at least 30% of mutant allele. In the present study, 
70% of the samples analyzed with the cobas test were 
macrodissected to maximize the test’s sensitivity; in 
contrast, no samples analyzed with the Idylla test were 
macrodissected, although the test is compatible with 
micro- or macrodissected tissue. In addition, the Idylla 
test detected a BRAF mutation in one unprocessed FFPE 
sample that MiSeq analysis revealed to have less than 5% 
BRAF mutation (i.e., 4.6% V600E), whereas the cobas 
test did not detect this mutation even in tissue that had 
been macrodissected. These findings suggest that Idylla 
can detect all clinically relevant BRAF V600 mutations 
and that, compared with the cobas test, Idylla has a higher 
sensitivity for detecting BRAF V600 mutations and thus 
could be used to identify a greater number of patients who 
may benefit from treatment with a BRAF inhibitor.
In conclusion, the IdyllaTM BRAF Mutation Test, 
which offers an integrated and sensitive “sample-to-
result” approach to detecting BRAF V600 mutations in 
FFPE samples, has a high concordance with routinely 
used methods for detecting BRAF V600 mutations in 
such samples.
Table 4: Tumor types of 100 patients with advanced cancers with known BRAF V600 status from 
the CLIA laboratory tested with Idylla
Tumor type No. of patients No. of BRAF V600 mutations 
detected (CLIA)
No. of BRAF V600 mutations 
detected (Idylla)
Melanoma 38 34 33
Colorectal cancer* 25 9 9
Papillary thyroid cancer 12 12 12
Ovarian cancer 5 1 1
Cholangiocarcinoma 3 2 2
Head and neck cancer 3 0 0




Non-small cell lung cancer 2 2 2
Esophageal cancer 1 0 0
Adrenocortical cancer 1 0 0
Prostate cancer 1 1 0




Glioblastoma 1 1 1
Thymoma 1 0 0
*One wild-type sample from CLIA showed BRAF V600 mutation on Idylla and one BRAF V600-mutant sample from 




From May 2012 until April 2014, patients with 
advanced cancers referred to the Department of Investi-
gational Cancer Therapeutics at MD Anderson Cancer 
Center were enrolled in the study. FFPE tumor tissue 
samples from these patients were tested for BRAF V600 
mutations in MD Anderson’s CLIA-accredited Molecular 
Diagnostics Laboratory. Patients had to have enough 
archived tissue to allow the study and patient accrual 
was enriched to ensure that at least 60% of patients in 
the study had BRAF V600 mutations. Patient registration 
in the database, tumor pathology assessment, and tumor 
mutation analysis were performed at MD Anderson. The 
study was conducted in accordance with MD Anderson’s 
Institutional Review Board guidelines. Additional FFPE 
tumor tissue samples from cancer patients who had signed 
an Institutional Review Board– or Ethical Committee–
approved informed consent form were acquired through 
commercial suppliers (OriGene Technologies, Inc., 
Rockville, MD; Asterand Europe, Royston, Hertfordshire, 
United Kingdom).
BRAF V600 mutation detection with the IdyllaTM 
BRAF mutation test
The IdyllaTM system (Biocartis, Mechelen, Belgium) 
is a random-access molecular diagnostic system that 
provides quantitative allele-specific real-time PCR–based 
sample-to-result functionality using a disposable cartridge 
that can detect and quantify up to 30 molecular biomarker 
groups from a variety of solid and liquid samples, 
including plasma and FFPE tissue. The instrument is 
composed of a sample preparation module integrated 
with a combined PCR thermocycling and fluorescence 
detection module. For FFPE specimens, the sample 
preparation module uses high intensity focused ultrasound 
technology to emulsify the paraffin and simultaneously 
rehydrate the tissue sample in an aqueous solution, thereby 
liberating DNA. Nucleic acids are then transported via 
microfluidic channels in the cartridge into 5 separate PCR 
chambers that contain pre-deposited dried PCR reagents 
(i.e., primers, probes, and enzymes). Each PCR chamber 
allows for the identification of up to 6 different biomarker 
groups (30 biomarker groups total), each of which can be 
composed of multiple individual biomarkers.
The Idylla BRAF Mutation Test (Biocartis, Mec helen, 
Belgium) is a single-use cartridge-based test designed to 
detect the nucleotide G1798 > A and T1799 > A changes 
in the BRAF gene with a sensitivity limit of 1% BRAF 
mutant DNA in wild-type background. The G1798 > A 
change is present in patients with V600K, V600R, and 
V600M mutations, whereas the T1799 > A change is 
present in patients with V600E, V600K, V600E2, and 
V600D mutations. The test requires an analytic time of 
about 90 minutes and a hands-on time of about 2 minutes. 
Once the sample is inserted into the cartridge and the 
lid is closed, the cartridge is sealed, thereby eliminating 
the possibility of cross-contamination between different 
samples. The test does not require that FFPE samples 
be manually deparaffinized or preprocessed; all reagents 
required for sample preparation (i.e., liberation of DNA 
from the FFPE section) and real-time PCR detection 
are included in the IdyllaTM cartridge. Although the 
test is compatible with macrodissected FFPE material, 
unprocessed FFPE sections were used in this study. For the 
clinical concordance analyses in the present study, a single 
10-μm section per FFPE sample was processed according 
to the manufacturer’s instructions by a molecular biology-
trained operator who was blinded for the results of the 
reference methods.
BRAF V600 mutation detection with the cobas 
4800 BRAF V600 mutation test
The cobas 4800 BRAF V600 mutation test (Roche 
Molecular Systems, Pleasonton, CA) was performed 
according to the manufacturer’s instructions at the College 
of American Pathologists– and CLIA-accredited molecular 
laboratory of HistoGeneX (Antwerp, Belgium). Briefly, 
5-μm sections were stained with hematoxylin and eosin 
and examined by a certified pathologist who delineated 
the tumor areas and determined the tumor cell content. For 
optimal sensitivity, macrodissection was used to enrich the 
tumor area. DNA from two 5-μm sections was isolated 
using the cobas DNA Sample Preparation Kit (Roche 
Molecular Systems, Pleasonton, CA), diluted to 5 ng/μl, 
and tested on a cobas 4800 System v2.0 (Roche Molecular 
Systems) according to the manufacturer’s instructions by 
a molecular biology-trained operator who was blinded for 
the IdyllaTM and MiSeq results.
BRAF V600 mutation detection with the MiSeq 
deep sequencing system
For BRAF V600 mutation detection with the MiSeq 
deep sequencing system (Illumina, San Diego, CA), DNA 
was first extracted from 10-μm FFPE sections using 
a QIAamp FFPE tissue DNA extraction kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instructions and eluted in 50 μl of elution buffer. 
Different samples’ DNA was normalized to 10 ng/μl 
based on measurement by Nanodrop (Thermo Fisher 
Scientific, USA), and an amplicon surrounding the BRAF 
V600 codon was generated using the forward primer 
5′-CTACTGTTTTCCTTTACTTACTACACCTCAGA-3′ 
and the reverse primer 5′-ATCCAGACAACTGTTCAA 
ACTGATG-3′. The DNA samples were combined 
with a PCR reaction mixture consisting of 10 mM Tris, 




0.2 mM dNTPs, 2 U FastStart Taq DNA polymerase (Roche 
Diagnostics, Rotkreuz, Switzerland), and 2 μl DNA input. 
The mixture was then subjected to PCR thermocycling for 
10 minutes at 95°C followed by 50 cycles of denaturation at 
95°C for 10 seconds, annealing at 62°C for 15 seconds, an 
extension step of 1 minute at 72°C, and a final extension step 
of 7 minutes at 72°C. The PCR products were visualized on 
Experion gel to confirm the presence of a single band of 
the correct length. Subsequent steps, including PCR product 
purification, sample barcoding, preparation of the MiSeq 
sequencing library, MiSeq sequencing, and bioinformatics 
data analysis, were performed by the Nucleomics Core at 
the Vlaams Instituut voor Biotechnologie (Gent, Belgium). 
At least 5000x coverage of the target region in each sample 
was required for MiSeq to have sufficient sensitivity. 
During the data analysis, the mutation threshold percentage 
for variant reporting was set at 1% mutant allele in a wild-
type background to identify all mutations occurring in at 
least 1% of the sample DNA.
BRAF V600 mutation testing in MD Anderson’s 
Molecular Diagnostics Laboratory
Archived tumor tissues obtained from enrolled 
patients’ primary or metastatic sites using routine 
diagnostic and/or therapeutic procedures were subjected 
to mutation testing in the CLIA–certified Molecular 
Diagnostics Laboratory in the Division of Pathology and 
Laboratory Medicine at MD Anderson. All histologies were 
centrally reviewed at MD Anderson. DNA was extracted 
from microdissected paraffin-embedded tumor sections 
and analyzed using a PCR-based DNA sequencing method 
for BRAF V600 mutations utilizing primers designed by 
the Molecular Diagnostics Laboratory. In January 2011, 
the assay was changed to mass spectrometric detection 
(MassARRAY, Sequenom, San Diego, CA), and in March 
2012, the assay was changed to next-generation sequencing 
(Ion Torrent, Life Technologies, Carlsbad, CA). The lower 
limit of detection is approximately 5–10%.
Statistical analysis
Concordance among mutation analyses was assessed 
using the kappa coefficient, sensitivity, specificity, 
and positive and negative predictive values, which 
were calculated using the GraphPad software program 
(GraphPad Software, Inc.; La Jolla; CA).
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